EU Conditional Approval Should Be A Drug Development Tool, Not A Rescue Remedy
This article was originally published in SRA
Executive Summary
Pharmaceutical companies in the EU should see conditional marketing authorization as a useful drug development planning tool, rather than as a "rescue option" to be used when they are unable to secure a full marketing authorization because they have not generated the required additional data, according to a senior European Commission official.
You may also be interested in...
Australian Provisional Approval Pathway To Get Tough On Sponsors Upfront
Plans by Australia’s Therapeutic Goods Administration to develop a provision approval pathway for drugs have moved up a gear.
Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System
Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, has been recommended for conditional marketing authorization in the EU pending the results of an ongoing Phase III study. The conditional approval system itself is under scrutiny regarding the fulfilment of obligations.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.